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I 
Abstract  
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive 
degeneration of upper and lower motor neurons in the brain and spinal cord, for which there is no 
cure. Activation of the stress-induced c-Jun N-terminal kinase (JNK) signaling pathway, a critical 
mediator of neuronal apoptosis and axon degeneration, is evident in ALS and is therefore considered 
a potential target to prevent neurodegeneration. Pharmacological inhibition of an upstream activator 
of the JNK pathway, the mitogen-activated protein kinase kinase kinase (MAP3K12), has 
demonstrated neuroprotection in vitro as well as suppression of pathway activation in vivo. These 
observations, along with the largely neuronal-specific expression of MAP3K12, makes inhibition of 
this kinase a promising therapeutic target for ALS. Furthermore, a pharmacodynamic (PD) blood 
biomarker would be beneficial to help assess efficacy of MAP3K12 inhibition. A crucial step to 
interpreting the PD effects of MAP3K12 inhibition using blood biomarkers is to acquire evidence of 
MAP3K12 protein expression in blood, which was the aim of this study. First, we found Map3k12 
transcript levels to be highly reduced in blood from Map3k12 conditional knockout (cKO) mice, 
demonstrating that these are excellent negative controls for studying MAP3K12 expression in blood. 
Next, three antibodies were identified that recognized mouse and human MAP3K12. Utilizing these 
antibodies, an intracellular flow cytometry method was developed that successfully detected 
MAP3K12 protein in human peripheral blood mononuclear cells (PBMCs). Collectively, our data 
provide evidence of MAP3K12 expression in human blood and thus pave the way for identifying PD 
blood biomarkers of MAP3K12 inhibition.  
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1 Introduction 
Neurodegeneration is a pathological condition involving the progressive loss of neurons1. ALS, also 
known as Lou Gehrig’s disease and motor neuron disease, is a rapidly progressive and invariably 
fatal neurodegenerative disease2. The disease is characterized by loss of motor neurons in the brain 
and spinal cord resulting in gradual weakness and ultimately paralysis of the innervated voluntary 
muscles. ALS is a rare disease with a prevalence of approximately 5 patients per 100,000 
individuals. The onset of disease usually occurs at a mean age of 55 and death follows typically 3-5 
years after diagnosis, mostly from respiratory failure. Approximately 10 % of ALS patients have the 
familial form of the disease, largely associated with genetic mutations with high penetrance, while 
about 90% of ALS cases occur sporadically. The cause for the vast majority of ALS cases is 
unknown, and to date, there is no cure2,3. 
Axon degeneration is a common pathological feature in many neurodegenerative diseases, 
characterized by the progressive breakdown of axons4,5. MAP3K12 has been demonstrated to play an 
important role in controlling axonal growth, apoptosis during neural development as well as 
neurodegeneration6. In response to neuronal injury, MAP3K12 regulates the mitogen-activated 
protein kinase (MAPK) cascade, leading to activation of the c-Jun N-terminal kinase (JNK) stress-
induced signaling pathway. This results in phosphorylation of the kinase JNK, causing it to 
translocate to the nucleus, where it in turn phosphorylates the protein c-Jun, leading to the 
transcription of JUN and other genes that mediate axon degeneration and apoptosis7. While 
inhibition of JNK has strong neuroprotective effects in vitro, a JNK inhibitor has yet to reach the 
clinic due to side effects. More specifically, complications would be expected due to JNKs 
ubiquitous expression and numerous functions outside neurodegeneration, including regulation of 
cell proliferation8-11. An alternative approach to direct inhibition of JNK is to target upstream 
MAP3K12 that is highly enriched in postmitotic neurons7, and could thus provide greater temporal 
and spatial selectivity. In fact, selective MAP3K12 inhibitors have demonstrated neuroprotective 
activity in vitro and suppression of c-Jun phosphorylation in injury models and therefore represent 
promising candidates for treatment of neurodegenerative diseases, such as ALS8,9,12. 
In this study, we sought to discover a peripheral biomarker to monitor the PD effects of MAP3K12 
inhibitors. MAP3K12 is found at the transcript level in blood13, which makes this a promising matrix 
for evaluating PD biomarkers of MAP3K12 activity. As MAP3K12 activity regulates transcription of 
c-Jun regulated genes, potential biomarkers could be measured using quantitative polymerase chain 
reaction (qPCR) that enable quantification of gene expression and is a suitable technique to use for 
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clinical applications such as monitoring drug responses14. In addition, collection of blood is a less 
invasive procedure compared to collection of cerebrospinal fluid (CSF) through lumbar puncture. 
Taken together, development of a blood biomarker would be of great therapeutic importance.  
A key step to evaluating the utility of blood-based biomarkers was to determine whether MAP3K12 
is expressed at the protein level. To achieve this, we used various techniques including western blot 
and flow cytometry. Confirmation of MAP3K12 protein expression in blood could pave the way for 
RNA sequencing (RNAseq) experiments to identify candidate genes that are modulated in response 
to inhibition of MAP3K12. This would be a first step to discover an expression-based blood 
biomarker to help predict MAP3K12 pathway inhibition.  
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2 Background 
2.1 Neuropathological features and genetics of ALS 
The primary pathology of ALS is the progressive degeneration of motor neurons in the motor cortex, 
brain stem and spinal cord (Fig. 1). The etymology of ALS reflects both the loss of spinal motor 
neurons (lower motor neurons), causing atrophy of target muscles (amyotrophy), and the 
degeneration of descending corticospinal neurons (upper motor neurons), causing scarring of axons 
in the lateral tracts of the spinal cord (lateral sclerosis)2. Similar to other neurodegenerative disorders 
the disease starts locally and progressively spreads, causing atrophy and weakness of muscles 
throughout the body2,15. 
 
 
 
 
 
 
 
 
 
 
The onset location and specific early symptoms depend on which motor neurons are first afflicted. 
The majority of patients have spinal-onset ALS, where motor neurons in the motor cortex and spinal 
cord are the first to degenerate. This form of the disease is characterized by asymmetric weakness in 
limbs, where symptoms including muscle atrophy and twitching indicate involvement of lower motor 
neurons, while hyperreflexia and hypertonia reflect upper motor neuron degeneration. 
Approximately 20% of patients present bulbar-onset ALS causing degeneration of brain stem motor 
neurons. These neurons innervate muscles of the mouth and throat and thus give rise to early 
symptoms such as speech and swallowing difficulties. Patients with spinal-onset ALS have an 
average survival time of 3-5 years following diagnosis while patients presenting bulbar-onset have 
an even worse prognosis with an average of 2 years16.  
Figure 1. ALS causes degeneration of motor 
neurons in the brain and spinal cord. ALS 
affects the descending upper motor neurons 
(originating in motor cortex projecting into the 
brain stem and spinal cord) and the lower motor 
neurons (projecting from the lumbar tract into 
skeletal muscles). Artwork retrieved from 
“Decoding ALS: from genes to mechanism” on 
06/22/17 [doi:10.1038/nature20413]. 
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Sporadic ALS (sALS) is the most common form of the disease and accounts for about 90% of all 
cases, with the majority having unknown etiology and lacking clear genetic cause. The remaining 
10% are cases of familial form of ALS (fALS) that are mainly caused by genetic inheritance17. In 
1993, fALS causative mutations were found in the gene SOD1, encoding the antioxidant enzyme 
superoxide dismutase 1. Since then, advancements in DNA sequencing technology have led to the 
discovery of a number of other genes, including C9orf72, TARDBP and FUS, in which mutations 
cause ALS16,18. The rapid progress in genetics of ALS combined with histological discoveries from 
post-mortem studies of ALS cases have provided insight into the molecular mechanisms and 
pathways underlying the disease19. 
Glutamate excitotoxicity has been suggested as a major pathogenic mechanism in ALS20. 
Excitotoxicity occurs from excessive stimulation of glutamate receptors that leads to an overload of 
neuronal calcium influx, which in turn triggers neurodegeneration. Glutamate excitotoxicity has also 
been implicated in axon degeneration, which is an early pathological feature in ALS20-22. Thus, it is 
of great importance to get a better understanding of how excitotoxicity could initiate pathways 
mediating neuronal death and axon degeneration. 
2.2 The role of MAP3K12 in axon degeneration and neuronal apoptosis 
MAPKs are a family of evolutionary-conserved serine-threonine protein kinases that are expressed in 
all eukaryotic cells where they control a diverse set of cellular processes including proliferation, 
differentiation, stress response and apoptosis23,24. Multiple MAPKs exist and are components of a 
phosphorylation cascade that relay and amplify intracellular signals in response to a variety of 
extracellular stimuli including cytokines, hormones, neurotransmitters, growth factors and cellular 
stress23. Each cascade consists of at least three kinases, including MAPK and two of its upstream 
kinases, MAPK kinase (MAP2K) and MAPK kinase kinase (MAP3K). Upon stimulation, MAP3Ks 
become activated and then phosphorylate and activate MAP2Ks, which in turn phosphorylate 
MAPKs. This sequential activation of MAPK ultimately leads to activation of target regulatory 
proteins controlling cellular programs24.  
The JNK stress-induced signaling pathway is one of the major MAPK pathways that have been 
identified in mammals23,24. This pathway takes its name after the JNK group of MAPKs, 
compromising the three isoforms JNK1, JNK2 and JNK3 (also known as MAPK8, MAPK9 and 
MAPK10, respectively). The JNK pathway is involved in multiple physiological processes including 
control of axon degeneration, neuronal apoptosis as well as neuronal homeostasis23. MAP3K12 is a 
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mixed-lineage protein kinase, which is mainly expressed in neurons, and can function as an activator 
of the JNK pathway24,25. MAP3K12 mediated pathway activation and subsequent neurodegeneration 
is evident in cultured dorsal root ganglion (DRG) neurons from mice in response to nerve growth 
factor (NGF) deprivation7. Moreover, axonal injury causes upregulation of MAP3K12 protein 
expression in retinal ganglion cells (RGCs) from mice26.  
In response to a variety of neuronal stresses, dual specificity mitogen-activated protein kinase kinase 
4 and 7 (MAP2K4 and MAP2K7) become activated by MAP3K12 and in turn activate JNK2 and 
JNK37,11,27 (Fig. 2). Upon activation, phosphorylated JNKs translocate to the nucleus where they 
phosphorylate the protein c-Jun which in turn upregulates expression of pro-apoptotic genes. 
Interestingly, MAP3K12 mediated axon degeneration seems to be c-Jun independent and caused by 
phosphorylation of distinct JNK targets7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 The therapeutic potential of inhibiting the MAP3K12/JNK pathway in ALS  
ALS is a disease with high-unmet need and as of yet, no good therapeutic options exist. The standard 
of care includes the drug Riluzole, which extends survival by about two months over 18 months of 
treatment. Unfortunately, patients gain no improvements in overall function or muscular strength and 
the treatment comes with many side effects, including fatigue and nausea28. Recently, the U.S Food 
and Drug Administration (FDA) approved a new drug, Radicava. This drug slowed the functional 
decline in a trial of patients with early-stage ALS, but the effects on survival have yet to be 
evaluated29. In order to develop novel disease modifying treatments that can change the course of 
21
Figure 2. A model for apoptosis and axon degeneration through 
MAP3K12 mediated activation of the JNK stress-induced 
pathway. MAP3K12 is activated in response to neuronal stress 
leading to the sequential activation of MAP2K4/7 and JNK 2 and 3. 
Next, phosphorylated JNKs are transported to the nucleus where 
they phosphorylate c-Jun, which in turn leads to transcription of 
genes mediating apoptosis.  Downstream JNK-activated targets 
mediate axon degeneration through a c-Jun independent process.  
MAP3K12 
MAP2K4/7 
JNK2/3 
c-Jun P- 
Apoptosis 
Axon  
Degeneration 
Neuronal stresses 
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this disease and improve patient survival, it is of great importance to advance the understanding of 
the molecular mechanisms mediating pathogenesis of ALS.  
Increased levels of phosphorylated c-Jun, a marker for JNK pathway activation, have been found in 
the spinal cord of ALS patients and ALS mouse models30-32. Reductions in apoptosis, axon 
degeneration and phosphorylated c-Jun levels have been observed in cultured primary DRG neurons 
from Map3k12 knockout (KO) mice embryos compared to WT controls, following cellular stress 
induced through NGF withdrawal7. Interestingly, global deletion of Map3k12 in adult mice strongly 
protects RGCs from apoptosis following axonal injury via optic nerve crush26. Furthermore, 
Map3k12 cKO adult mice have a reduction in neurodegeneration following excitotoxicity–induced 
cell death in vivo33. Collectively, these studies suggest that MAP3K12 regulates the JNK stress-
induced pathway following NGF withdrawal, axonal injury and excitotoxicity and that loss of 
MAP3K12 is neuroprotective. These findings, in conjunction with the implicated glutamate 
excitotoxicity pathogenic process in ALS21, strongly suggests that inhibition of MAP3K12/JNK 
pathway could be a potential therapeutic target for treatment of ALS.   
The role of the JNK stress-induced pathway signaling in neurodegenerative diseases, such as ALS, 
has resulted in significant efforts towards developing inhibitors of this pathway8. Inhibition of JNK 
protects cortical neurons and RGCs against excitotoxicity-induced death in vitro as well as in vivo 
following brain injury34,35. However, the ubiquitous expression of JNKs along with their roles in 
both pathological and physiological functions implies that potential side effects could arise from use 
of JNK inhibitors. Consequently, there has been no approval of JNK inhibitors for use in humans8-11. 
Thus, efforts have been made to find an alternative approach to direct inhibition of JNK. The 
selective expression of MAP3K12 in the brain in conjunction with its role as an upstream activator 
of the JNK pathway makes it a promising therapeutic candidate. Recently, novel selective MAP3K12 
inhibitors have been developed through high-throughput screening against the catalytic kinase 
domain of MAP3K12. These small-molecule inhibitors have strong neuroprotection in vitro in rat 
primary DRG neurons and embryonic stem cell (ESC) derived RGCs8,36. Furthermore, inhibition of 
MAP3K12 in vivo suppressed c-Jun phosphorylation in both a mouse optic nerve crush model of 
axonal injury and in a Parkinson’s disease mouse model of neurodegeneration8. Taken together, 
these findings suggest a potential for MAP3K12 inhibitors as disease modifying therapeutics for 
neurodegenerative diseases. 
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2.4 Using expression-based peripheral blood biomarkers to help predict 
MAP3K12 inhibition 
Biomarkers are important tools in drug discovery and development with a wide range of 
applications. These include evaluation of drug safety, efficacy, changes in biological pathways and 
target engagement37. The need for PD biomarkers in ALS drug development is of great importance 
since demonstration of drug efficacy and target engagement in the nervous system could help guide 
dose selection, contribute to reducing the length and increasing the chances of successful clinical 
trials38,39.   
Here, we sought to identify a gene expression-based biomarker to measure the PD effects of 
MAP3K12 inhibitors. This has advantages over assaying for the phosphorylation state of the MAPKs 
due to the transient nature of these events40. Furthermore, MAP3K12 mediated transcriptional 
changes of c-Jun regulated genes could be detected using RNAseq and easily measured using qPCR, 
and are thus promising biomarkers of MAP3K12.  
MAP3K12 is expressed at the RNA level in human peripheral blood13, which makes blood a 
promising source for measuring PD biomarkers of MAP3K12. However, interpretation of the PD 
effects of MAP3K12 inhibition requires evidence of protein expression, which has not, to the best of 
our knowledge, been identified in blood. Therefore, the main focus of this study was to investigate 
whether MAP3K12 protein is expressed in human peripheral blood.  
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3 Material and Methods 
3.1 Mouse models 
Map3k12 cKO mice were generated by crossing mice having exons 2-5 (DNA encoding kinase 
domain of MAP3K12) flanked by loxP sites (Map3k12loxp/loxp)7 with mice carrying a 
cytomegalovirus (CMV) early enhancer/chicken 𝛽-actin (CAG) promotor driven Cre recombinase-
estrogen receptor transgene (Cre-ERT)41 obtained from The Jackson Laboratory. To induce 
Map3k12 recombination and excision of Map3k12 in brain and peripheral tissue, both 
Map3k12loxp/loxp/Cre-ERTpos mice (referred to as Map3k12loxp;Crepos) and their littermate controls 
(Map3k12loxp;Creneg) were fed tamoxifen for 3 weeks, put back on a regular diet and used in 
experiments after approximately one year.  
All animal procedures were reviewed and approved by the Institutional Animal Care and Use 
Committee at Genentech and are in accordance with the NIH’s Guide for the Care and Use of 
Laboratory Animals. 
3.2 qPCR 
Total RNA was isolated from whole blood and brain tissue (collected from Map3k12loxp;Crepos and 
Map3k12loxp;Creneg mice) using the RiboPure™ Blood RNA Purification Kit (Invitrogen) and the 
RNeasy Mini Kit (Qiagen), respectively. RNA purity and concentrations were measured using a 
NanoDrop Spectrophotometer and equal amounts of cDNA were synthesized using the High-
Capacity cDNA Reverse Transcription Kit (Thermo Fischer Scientific). qPCR analysis was 
performed using TaqMan Fast Advanced Master Mix (Applied Biosystems) and pre-designed 
TaqMan Gene Expression Assays (Applied Biosystems) on a ViiA 7 Real-Time PCR system 
(Applied Biosystems).  Assay ID for each pair of Map3k12 TaqMan primers (labeled with FAM dye) 
were as follows: Mm01303169_m1 (referred to as probe 1), Mm01296205_m1 (referred to as probe 
2) and Mm01296200_g1 (referred to as probe 3). Gapdh was used as endogenous control and 
detected using a VIC-labeled set of TaqMan primers (Assay ID: NM_008084.2, Applied 
Biosystems). Gapdh and Map3k12 primers were multiplexed. The qPCR data was analyzed using 
ΔCt (Ct = cycles to threshold) values that demonstrate the difference of gene expression between 
Map3k12 and Gapdh as well as ΔΔCt values that demonstrate difference between ΔCt for 
Map3k12loxp;Crepos mice and Map3k12loxp;Creneg mice . The 2!!!!" – method was used to calculate 
the relative expression of Map3k12 between Map3k12loxp;Crepos mice and Map3k12loxp;Creneg mice. 
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Prism7 (Graphpad) was used for statistical analysis with p-values determined by the Two stage set-
up method of Benjami Krieger and Yekutieli.  
3.3 Cell cultures 
Stable MAP3K12 expressing cells were generated as previously described42. Briefly, human 
MAP3K12 was cloned into a pTRE2hyg vector and subsequently transfected into 293 Tet-ON cells.  
Selected cells were grown to 70-80 % confluence and then subjected to 3 uM doxycycline (DOX) to 
induce MAP3K12 expression. 24 hours later, cells were either lysed for western blot analysis or 
trypsinized for flow cytometry analysis. 
3.4 Western blotting 
Brain tissue (~500 ug/mouse) was harvested from Map3k12loxp;Crepos and Map3k12loxp;Creneg mice 
and lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, 150 mM NaCl, 2 mM 
EDTA, 10% NP-40, 0.1% SDS, pH 7.4) containing protease and phosphatase inhibitor cocktails 
(Roche) and benzonase nuclease (Sigma Aldrich) using a tissue homogenizer (Bertin) with 1.4 mm 
ceramic beads (Qiagen). Brain lysate was centrifuged at 20,000 x g at 4℃ for 15 min for collection 
of soluble proteins in supernatant. 293 cell cultures were lysed in 1 mL of RIPA buffer for 15 min at 
4℃ followed by centrifugation at 20,000 x g at 4℃ for 15 min for collection of soluble protein. 
Protein amounts were determined using Pierce™ BCA protein assay (Thermo Fischer Scientific) and 
iMark™ Microplate Absorbance Reader (Bio-rad). 
Lysate was resuspended in NuPAGE LDS Sample Buffer (Invitrogen) containing NuPAGE Sample 
Reducing Agent (Invitrogen), incubated at 70℃ for 10 min and loaded on 4-12% Bis-Tris gels 
(Invitrogen). Gels were run in NuPAGE MOPS SDS Running Buffer (Invitrogen) at 200V using 
Powerpac™ power supply (Bio-rad).   
Proteins were transferred onto 0.2 µm nitrocellulose membranes using iBlot® 7-Minute Blotting 
System (Invitrogen). To block unspecific binding, blotted membranes were incubated with 5% skim 
milk (Bio-rad) in TBS-Tween (50 mM Tris, 150 mM NaCl 0.1% Tween 20, pH 7.5) for 1 h at room 
temperature (RT). For immunodetection, membranes were incubated for 24 h at 4°C with primary 
antibodies (Table S1), washed 3x5 min with TBS-Tween and incubated for 2 h at RT with secondary 
HRP-conjugated antibodies (Table S1).  Blots were developed with enhanced chemiluminescence 
(SuperSignal West Dura or SuperSignal West Dura Femto) detection system (Thermo Fisher 
Scientific) and imaged using ImageQuant LAS 4000 (GE Healthcare).  
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3.5 Isolation of human PBMCs 
Human PBMCs were isolated from K2-EDTA treated peripheral blood of healthy donors by standard 
Ficoll-Paque Plus density gradient centrifugation (GE Healthcare) using phosphate-buffered saline 
(PBS) as salt balance solution. PBS was added to fresh blood at a 1:3 ratio, mixed and then layered 
onto Ficoll-Paque media at a 2:1 ratio and centrifuged at 800 x g for 20 min at RT (brake off). The 
layer of mononuclear cells was isolated using a sterile pipette. After washing with PBS, PBMCs 
were collected by centrifugation at 1500 rpm for 5 min at RT (brake on) and used in flow cytometry 
analysis. Cell viability was determined by trypan blue dye exclusion using the Countess Automated 
Cell Counter (Invitrogen). 
 
3.6 Flow cytometry analysis 
For flow cytometry analysis of 293 cells, adherent cells were grown to 70-80 % confluence and then 
harvested and dissociated using Trypsin-EDTA 0.25% (Gibco) at 37℃ for 5 min.  
Fixation and permeabilization of 293 cells and isolated PBMCs were performed as previously 
described43. 293 cell suspensions in staining solution (1% Bovine serum albumin in PBS) were 
incubated for 10 min at RT with Human BD Fc Block (BD biosciences) prior to immunostaining. 
Cells were stained with primary antibodies or isotype control (Table S1) for 1 h at RT, washed twice 
with staining solution and subsequently incubated with a secondary antibody coupled to a fluorescent 
dye (Table S1) for 30 min at RT. Cells were washed twice and then resuspended in staining media 
for flow cytometry analysis. Samples were acquired with a BD LSR Fortessa flow cytometer (BD 
biosciences) and 20,000-30,000 events were analyzed. Fluorescence was measured using Alexa 
Fluor 647 detection channel (laser line 647) and a FITC channel (laser line 488) was included as a 
control. Primary gates were set based on forward scatter (FSC) and side scatter (SSC) to exclude cell 
debris, dead cells and cell doublets. Positively stained cells were gated in accordance to cells stained 
with isotype controls. FlowJo software (Tree Star) was used for data analysis.  
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4 Results  
4.1 Map3k12 transcript is efficiently reduced in whole blood from Map3k12 cKO 
mice  
As previously described, Map3k12 cKO mouse models are useful for studying injury/stress-induced 
neurodegeneration. Here, we sought to investigate whether they can also be used for studying 
MAP3K12 mediated changes in gene and protein expression in blood. Additionally, an in vivo model 
could be useful to better understand the effects of inhibiting MAP3K12. Before analyzing MAP3K12 
protein expression in blood, we needed to assess whether cKO of Map3k12 results in an adequate 
loss of the transcript in blood.    
Here, we used Map3k12 cKO mice generated through Cre-lox recombination as previously 
described7,41. This KO technique enables inducible gene deletion at a designated time window, hence 
circumventing the embryonic lethality that can occur in germline Map3k12 KO mice33. A previous 
study confirmed that this method results in significant reduction in MAP3K12, on both gene and 
protein level in brain33, but the effects in blood have not been previously assessed. Since Cre-ERT is 
expressed throughout the body41, recombination should lead to reduced expression of MAP3K12 not 
only in nervous tissue, but also in peripheral blood. However, as opposed to neurons that enter a 
post-mitotic state early during development, hematopoietic stem cells are multipotent and can renew 
in the bone marrow throughout life44. Consequently, substantial cKO of Map3k12 is more difficult to 
achieve in blood than in brain.  
To investigate whether Map3k12 had been effectively reduced at the mRNA level in blood, qPCR 
analysis was performed using three different probes specific for different sequences of Map3k12 
(Fig. 3A). Gene expression quantification using probe 1 (Fig. 3, B and E) demonstrated a significant 
increase in ΔCt values in blood from Map3k12loxp;Crepos mice compared to Map3k12loxp;Creneg mice 
and the relative gene expression was quantified to be 30%. As expected, ΔCt values and relative 
gene expression were reduced in Map3k12 levels in brain from Map3k12loxp;Crepos (~ 30% relative 
gene expression). Similarly, there was a significant increase in ΔCt values in blood from 
Map3k12loxp;Crepos mice compared to Map3k12loxp;Creneg mice and the relative expression of 
Map3k12 measured to approximately 15% using probe 2 (Fig. 3, C and F) and 30% using probe 3 
(Fig. 3, D and G). An approximate 30 % reduction of Map3k12 transcript was observed in brain 
tissue of the cKO mice. Quantification of Map3k12 in blood from one of the Map3k12loxp;Crepos mice 
resulted in lower ∆Ct values compared to the other mice, across all three experiments (Fig. 3B-D). In 
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contrast, ∆Ct values in brain were similar between all mice, suggesting that the variability in blood 
emerged from issues with sample collection and processing. 
Collectively, these data demonstrate a considerable reduction of Map3k12 in blood from 
Map3k12loxp;Crepos mice compared to Map3k12loxp;Creneg mice. Map3k12 expression was 
significantly reduced in brain tissue from Map3k12loxp;Crepos mice compared to Map3k12loxp;Creneg 
mice, which correlates well with the observations made in a previous study33.  Interestingly, the 
reduction observed with both upstream and downstream probes indicates that deletion of the exons 
encoding the kinase domain of MAP3K12, leads to loss of the entire transcript in both blood and 
brain tissue.  Moreover, these data demonstrate that three weeks of tamoxifen treatment is adequate 
to achieve long-lasting reduction of Map3k12 transcript in blood allowing us to assess changes, on 
both gene and protein level, mediated by MAP3K12. 
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Figure 3. qPCR analysis of Map3k12 expression in whole blood and brain tissue from Map3k12loxp;Crepos mice 
relative to Map3k12loxp;Creneg mice. (A) Gene expression analysis was performed using three Map3k12 specific 
TaqMan probes targeting different sequences of the gene (positions marked on the resulting Map3k12 transcript). 
Probe 1 spans two non-coding exons upstream of the deleted region, probe 2 spans two coding exons, one of them 
within the deleted region and probe 3 spans two coding exons downstream of the deleted region. (B and E) Gene 
expression quantification using probe 1; (C and F) using probe 2; (D and G) using probe 3. (B-D) Expression of 
Map3k12 is presented as ∆Ct (normalized to Gapdh). Error bars represent +/- SEM for n ≥ 3. Not significant (ns). p > 
0.1; * p < 0.1; ** p < 0.01;  *** p < 0.001. (E-G) Boxplot representation displays median value (bold line) of relative 
gene expression (2!!!!") of Map3k12 between Map3k12loxp;Crepos mice and Map3k12loxp;Creneg mice (dashed line). 
Whiskers represent min and max values for n ≥ 3.  
probe 1 
upstream 
(spans non-coding exons) 
deleted region  
(coding exons 2-5) 
coding exon 1 
5’ 3’ 
probe 2 
spans one of the deleted exons 
probe 3 
downstream  
(spans coding exons) 
Map3k12 transcript 
A 
  
14 
4.2 Three antibodies recognize MAP3K12 by western blot 
To investigate whether MAP3K12 is expressed at the protein level in blood, the first step was to 
identify specific and sensitive anti-MAP3K12 antibodies. More specifically, we sought to find 
antibodies recognizing both human and mouse MAP3K12 to study the protein in a variety of 
immunostaining applications including western blot, flow cytometry and immunohistochemistry. For 
this purpose, seven anti-MAP3K12 antibodies (Table S1, Ab 1-7) were screened by western blot. 
Out of these seven antibodies, immunoblotting with three demonstrated appreciable levels of 
MAP3K12 in brain tissue from Map3k12loxp;Creneg mice and as anticipated, the protein levels in 
brain tissue from the  Map3k12loxp;Crepos mice were highly reduced, mirroring the mRNA data (Fig. 
4A). Utilizing a 293 stable cell line where MAP3K12 expression was under the control of DOX, the 
same three sets of antibodies were also able to detect human MAP3K12. Notably, faint bands 
corresponding to MAP3K12 were observed for the non-induced 293 cells as well, and this likely is 
due to basal activity of the promoter causing leaky expression of MAP3K12 (Fig. 4B). The 
remaining antibodies were unable to recognize both mouse and human MAP3K12, which was 
concluded based on the lack of bands at the appropriate molecular weight (Fig. 4, A and B). 
Although bands at the molecular weight of MAP3K12 were observed for 293 cells using Ab 4, these 
were concluded non-specific given the absence of any noticeable differences between the induced 
and non-induced lanes.  
To summarize, the antibody screen resulted in three antibodies that successfully recognize both 
mouse and human MAP3K12. Interestingly, each of these antibodies recognize different regions of 
MAP3K12, where Ab 1 recognizes the C-terminus, Ab 2 the N-terminus and Ab 3 recognizes a 
sequence within the center region of MAP3K12. As depicted by the intensity of bands, the sensitivity 
of these three antibodies differs. A more sensitive chemiluminescence substrate was required for 
detection of MAP3K12 using the C-terminus specific antibody (Ab 1) than for the two other 
antibodies, suggesting it is less sensitive. Moreover, the center-specific antibody (Ab 3) yielded the 
strongest bands with a 10 s exposure, compared to a 30 s exposure that was used for Ab 1 and Ab 2.  
Evidently, Ab 3 outperformed the other two MAP3K12 antibodies, and was concluded to be the most 
promising candidate for further protein analysis.  
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Figure 4. Western Blot analysis of seven different anti-MAP3K12 Abs (Ab 1-7). (A) MAP3K12 
immunoreactivity in brain tissue lysates from Map3k12loxp;Creneg mice and MAP3K12loxp;Crepos mice. 𝛽-actin was 
used as internal loading control. (B) MAP3K12 reactivity in lysates from a MAP3K12 293 stable cell line ± DOX to 
control expression of MAP3K12.  𝛽-actin was used as internal loading control. 
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4.3 Evidence of MAP3K12 protein expression in human PBMCs 
The antibody screen resulted in three antibodies that recognize MAP3K12 by western blot, and we 
next asked whether they could be used for protein analysis by flow cytometry. This technique is 
useful for studying protein expression and has the capability to measure single cell events. An 
important advantage of flow cytometry over biochemical applications such as western blot is the 
possibility to analyze samples with complex cell populations, such as human PBMCs, that are 
composed of a heterogeneous population of immune cell types43. Thus, it is a promising method to 
detect intracellular expression of MAP3K12 in peripheral blood and could provide information about 
which populations expresses it.  
Utilizing the three antibody candidates from the western blot screen, we developed an intracellular 
flow cytometry method to measure human MAP3K12. This was achieved through fixation and 
permeabilization of 293 stable cell line where expression of MAP3K12 was inducible in the presence 
of DOX. The cells were then stained with Ab 1, 2 and 3 followed by an Alexa-647 labeled secondary 
antibody (Table S1) and analyzed by flow cytometry. To discriminate MAP3K12 positive cells from 
negative cells, an IgG isotype control was used and the resulting gating scheme is presented in (Fig. 
S1, A and B).  
In general, the flow cytometry results mirrored the observations from our western blot experiments. 
A very small amount of MAP3K12 positively stained cells were detected for the non-induced 293 
cells with Ab 1 (Fig. 5A). In contrast, a large number of non-induced 293 cells stained positive with 
Ab 2 and Ab 3 (Fig. 5, B and C), but this was concluded to be due to leaky expression of MAP3K12, 
given that similar observations were made with these two antibodies in western blot. Importantly, 
noticeable shifts in fluorescence intensity between negative and positive DOX-induced cells were 
observed with all three antibodies with the vast majority of cells staining positive (Fig. 5, D-F). More 
specifically, the MAP3K12 center-specific antibody (Ab 3) displayed the greatest shift in intensity of 
DOX-induced 293 cells, which agrees with the previous observations made by western blot. 
Collectively, these results demonstrate that all three antibodies are suitable for intracellular flow 
cytometry analysis of MAP3K12, with Ab 3 demonstrating the greatest sensitivity for human 
MAP3K12.  
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Figure 5. Flow cytometry analysis of MAP3K12 expression in 293 cells ± DOX-induced MAP3K12 
expression following intracellular staining using Ab 1, Ab 2 and Ab 3. Representative dot plots depict 
the fluorescence intensity (-A in axis label refers to fluorescence area) and percentages of MAP3K12 
positive (+) cells and MAP3K12 negative cells (-). Representative histograms depict fluorescence 
intensity (x-axis) and number of cells (y-axis). (A-C) Analysis of non-induced 293 cells. (D-F) Analysis 
of DOX-induced 293 cells.  
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With a successfully developed intracellular flow method, we could next investigate MAP3K12 
protein expression in human peripheral blood. Human PBMCs were isolated from two healthy 
donors for subsequent flow cytometry analysis in accordance to the previously described flow 
cytometry method. The resulting gating scheme is presented in (Fig. S1, C and D).  
A slight shift in fluorescence intensity was observed for less than 15% of the PBMCs stained with 
the C-terminus specific antibody (Ab 1), suggesting minimal expression of MAP3K12 in these cells 
(Fig. 6A).  Although, the general absence of MAP3K12 positive cells could be due to the antibody 
not having the sensitivity required to detect the protein in PBMCs, given that this was the least 
sensitive antibody in previous western blot and flow cytometry analyses. Interestingly, a larger 
percentage of PBMCs stained positive with the N-terminus antibody (Ab 2) (Fig. 6B). This data is 
suggestive for possible expression of MAP3K12 protein in human blood, and remarkably, this kinase 
seems to be expressed by a high number of PBMCs. This was further corroborated by staining cells 
with Ab 3, the center-specific antibody, where an extensive shift in fluorescence intensity between 
negative and positive cells was observed, with the majority of cells staining positive for MAP3K12 
(Fig. 6C). Taken together, these data provide evidence of MAP3K12 protein expression in human 
PBMCs.  
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Figure 6. Flow cytometry analysis of MAP3K12 
expression in human PBMCs. Representative dot 
plots depict the fluorescence intensity (-A in axis label 
refers to fluorescence area) and percentages of 
MAP3K12 negative (-) cells and MAP3K12 positive 
(+) cells. Representative histograms depict fluorescence 
intensity (x-axis) and number of cells (y-axis). D1 = 
healthy donor 1; D2 = healthy donor 2. (A) Intracellular 
staining of PBMCs using Ab 1, (B) Ab 2 (C) and Ab 3.  
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5 Discussion 
Activation of the JNK stress-induced pathway is hypothesized to mediate neurodegeneration 
observed in ALS30-32. MAP3K12 is an essential upstream regulator of this stress-induced apoptotic 
signaling, and selective small-molecule inhibitors of this kinase have neuroprotective activity in vitro 
and suppression of JNK activation and subsequently downstream responses in injury models8,12. 
Thus, inhibition of MAP3K12 may provide a disease-modifying treatment option for 
neurodegenerative diseases, such as ALS. Gene expression-based peripheral blood biomarkers would 
be useful to assess the PD effects of MAP3K12 inhibitors, and for this reason, we asked whether 
MAP3K12 is expressed on a protein level in blood.  
Map3k12 cKO mouse models are useful negative control for assessing expression of MAP3K12 and 
its downstream targets in the central nervous system. Here, we demonstrated that Map3k12 transcript 
is significantly reduced, not only in brain tissue, but also in peripheral blood from Map3k12 cKO 
mice. Remarkably, at the time of gene expression analysis, over a year had elapsed since 
recombination had been induced through three weeks of tamoxifen treatment in these mice. This 
implies that this dosing regimen is sufficient to induce a long-lasting reduction in Map3k12 transcript 
in both brain and blood in Map3k12 cKO mice, and thus avoid the lethality observed in embryonic 
Map3k12 KO mice. Interestingly, down-regulation of the transcript was observed with probes 
targeting sequences within the deleted region of the gene, as well as upstream and downstream of it, 
suggesting that deletion of the exons encoding the kinase domain of MAP3K12 causes the entire 
transcript to be lost in blood. To summarize, the Map3k12 cKO mouse model was concluded to be an 
efficient negative control for assessment of MAP3K12 protein expression in blood as well as for 
identification of expression-based blood biomarkers following in vivo inhibition of MAP3K12.   
A crucial step towards identifying potential expression of MAP3K12 in blood was to find specific 
and sensitive anti-MAP3K12 antibodies. Here, we used western blot to screen a number of 
antibodies and found three that evidently recognize both human and mouse MAP3K12. Surprisingly, 
two bands were observed for Map3k12loxp;Creneg brain tissue blotted with Ab 2. A possible 
explanation for this is that the lower molecular weight band could correspond to a splicing variant of 
MAP3K12 that is only recognized by the N-terminus specific antibody. This in turn suggesting that 
the splicing event affects the center and C-terminus portion of the protein.   
Out of these three antibodies, the antibody targeting a sequence within the central region of 
MAP3K12 was concluded the most sensitive, hence a promising candidate for exploring MAP3K12 
expression in blood using both flow cytometry and western blot. Moreover, it is a potential candidate 
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for analyzing MAP3K12 using immunohistochemistry, which could enable in situ localization of 
MAP3K12 in different tissues. Establishing the localization and distribution of MAP3K12 in nervous 
tissue could help us get a better understanding of how it relays stress-induced apoptotic signaling.  
Utilizing the three antibodies from the western blot, we developed an intracellular staining method 
for detection of MAP3K12, which we then used to explore MAP3K12 expression in human PBMCs. 
These experiments revealed evidence of MAP3K12 expression in human blood. More specifically, 
MAP3K12 expression was detected with Ab 2 and Ab 3, which recognize the N-terminus and the 
central region, respectively. As would be expected based on previous protein analyses, flow 
cytometry analysis using the center-specific antibody (Ab 3) provided the strongest evidence of 
MAP3K12 expression in blood. Nonetheless, results using two anti-MAP3K12 antibodies of 
different specificity further support the existence of MAP3K12 protein in blood. However, flow 
cytometry analysis of MAP3K12 in PBMCs from Map3k12 cKO mice will help to bolster the 
evidence of MAP3K12 expression in peripheral blood cells. In addition, it would be of great interest 
to confirm the expression of MAP3K12 in mouse and human blood by a second, independent 
method such as western blot. For this purpose, a next step will be to develop an immunoprecipitation 
method to enrich for MAP3K12 in blood to allow for subsequent detection by western blot.      
The heterogeneity of human PBMCs makes it challenging to measure RNA expression, hence 
identification of specific cell types with relatively high MAP3K12 expression could enable us to 
narrow down the numbers of genes to study. Remarkably, a great shift in fluorescence intensity was 
observed for a small fraction of the MAP3K12 positive cells using Ab 3, suggesting that these cells 
express high levels of the protein. It would be interesting to characterize and identify these cells, 
since detection of specific cell populations expressing high levels of MAP3K12 could facilitate 
biomarker detection. Thus, a subsequent effort will be to identify specific cell populations expressing 
the protein by staining human peripheral blood with a variety of immune cell surface markers 
concurrently with anti-MAP3K12 antibodies. Additionally, flow cytometry analysis of peripheral 
blood from Map3k12 cKO mice would enable us to explore whether any cell populations are 
especially impacted by the loss of MAP3K12.  
In conclusion, we provide evidence of MAP3K12 expression in human peripheral blood, which 
implies that potential downstream changes in response to MAP3K12 inhibition could be a reflection 
of target engagement. These findings will allow us to perform RNAseq analysis to identify candidate 
genes changing in blood in response to MAP3K12 inhibition with the potential to discover 
expression-based PD blood biomarkers. 
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Supplemental Information 
 
# Antibody Target Description Species reactivity Supplier 
1 Anti-MAP3K12 C-terminus of MAP3K12 Rb mAb Ms, Hu Genentech 
2 Anti-MAP3K12 N-terminus of MAP3K12 Rb mAb Ms, Hu Genentech 
3 Anti-MAP3K12 Center region of MAP3K12 Rb pAb Ms, Hu 
Sigma Aldrich 
(#SAB2700169) 
 
4 Anti-MAP3K12 C-terminus of MAP3K12 Rb pAb Ms, Hu 
Abcam                       
(# ab37996) 
5 Anti-MAP3K12 Center region of MAP3K12 Rb pAb Ms, Rt, Hu 
Novus Biologicals 
(#NBP1-46063) 
6 Anti-MAP3K12 MAP3K12 (region N/A) Rb pAb Ms, Rt, Hu 
Biorbyt                      
(# orb335162) 
7 Anti-MAP3K12 MAP3K12 (region N/A) Ms mAb Ms, Hu 
Sigma Aldrich 
(#SAB1306766) 
8 β-Actin (13E5) Endogenous levels of total β-actin protein 
Rb mAb (HRP 
conjugate) 
Hu, Ms, Rt, Nhp, 
Bv, Po 
Cell signalling 
technology 
(#5125S) 
9 Alexa Fluor 647 Heavy and light chains of Rb IgG 
Do pAb (conjugated with 
Alexa Fluor® 647) Rb 
Biolegend 
(#406414) 
10 Rabbit IgG isotype control 
Control for Rb IgG 
antibodies Rb Rt 
Thermo Fischer 
Scientific (#02-
6102) 
11 Gt anti-Rb IgG Secondary 
Heavy and light chains 
of Rb IgG Gt pAb Rb 
Thermo Fischer 
Scientific (#31460) 
 
 
 
 
Table S1. Primary and secondary antibodies used in this study. Abbreviations: Rabbit (Rb), Mouse (Ms), Human (Hu), 
Rat (Rt), Non-human primate (Nhp), Bovine (Bv), Pig (Po), Do (Donkey), mAb (monoclonal antibody) and pAb 
(polyclonal antibody). 
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MAP3K12 - 
MAP3K12 - 
C
D
MAP3K12 - 
MAP3K12 - 
Figure S1. Gating strategy for flow cytometry analysis. Cells were selected based on FSC-area (FSC-
A) and SSC-area (SSC-A). Single cells were separated from doublets based on FSC-A and FSC-height 
(FSC-H). Fluorescence-detecting gates (dot plots and histograms) were set in accordance to cells stained 
positive with IgG isotype control (MAP3K12 -) and a secondary antibody fluorescence dye Alexa Fluor 
647 (-A in axis label refers fluorescence area). (A) Non-induced 293 cells. (B) DOX-induced 293 cells. 
(C) Human PBMCs from healthy donor 1 (D) and healthy donor 2.  
 
 
